Wc. Soeller et al., ISLET AMYLOID-ASSOCIATED DIABETES IN OBESE A(VY) A MICE EXPRESSING HUMAN ISLET AMYLOID POLYPEPTIDE/, Diabetes, 47(5), 1998, pp. 743-750
We have previously shown that hemizygous transgenic mice expressing hu
man islet amyloid polypeptide (hIAPP) in pancreatic beta-cells have no
diabetic phenotype, whereas in the homozygous state, they developed s
evere, early-onset hyperglycemia associated with impaired insulin secr
etion and beta-cell death. We investigated the possibility that when t
he hemizygous mice are crossed onto an obese, insulin-resistant strain
such as agouti viable yellow (A(vy)/a), they would exhibit a phenotyp
e more akin to human type 2 diabetes. The hIAPP-expressing A(vy) males
(TG-Y) displayed fasting hyperglycemia at 90 days of age and by 1 yea
r progressed to severe hyperglycemia relative to their nontransgenic c
ounterparts. Plasma insulin concentrations and pancreatic insulin cont
ent dropped 10- to 20-fold, suggesting severe impairment of beta-cell
function. Histopathological findings revealed beta-cell degeneration a
nd loss consistent with the drop in the plasma insulin concentration.
In addition, large deposits of IAPP amyloid were present in TG-Y islet
s, We conclude that in transgenic mice expressing hIAPP, insulin resis
tance can induce overt, slow-onset diabetes associated with islet amyl
oid and decreased beta-cell mass.